HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab

Phase 3

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

7 competitors in Colorectal Cancer

SLDBFrog Bacterium Therapy

BNTXautogene cevumeran

Phase 2

View Full Landscape

Drug Information

Target Indication

Colorectal Cancer

Clinical Trial

NCT05945901

Last updated: 10/29/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

JSKN003Phase 3

Advanced Solid Tumor

Irinotecan liposome、5-Fluorouracil、LeucovorinPhase 3

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

X0002 SprayPhase 3

KNEE OSTEOARTHRITIS

RocuroniumPhase 3

Neuromuscular Blockade

HRS-9190Phase 3

Neuromuscular Blockade

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts